- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04529629
Precise Diagnosis, Treatment and Prognostic Evaluation of Complicated Adrenal Tumor Diseases
The adrenal gland is an important organ that produces life hormones. There are many types of adrenal tumors, which tend to occur in young adults and affect the whole body. It has the dual threat: hormone secretion and tumor metastasis. At present, there are four major dilemmas in the clinical diagnosis and treatment of adrenal tumors: 1) Pulse secretion of the hormones, which are affected by many factors; and the diagnostic value of single hormone is limited; 2) Traditional imaging cannot accurately reflect the characteristics of hormone secretion. The prognosis cannot be accurately predicted; 3) The molecular characteristics of tumor cells and the microenvironment are unclear, making it difficult to implement early diagnosis and precise treatment; 4) Traditional pathology cannot determine the nature and long-term prognosis of the tumor, which makes the treatment delay, and the disease prognosis is extremely poor. It threatens the lives of patients.
Starting from solving the above-mentioned key problems in the early stage, the research team has systematically established new clinical diagnostic technologies, hormone dynamic tests to accurately assess hormone secretion and segmented blood collection hormone determination technologies to accurately locate adrenal tumors; A series of important research results have been published in Science, Lancet Diabetes & Endocrinology, Cell Research, etc To sum up, the goal of this research is improving the early diagnosis rate of complicated adrenal tumors especially in malignant tumors, developing the optimal treatment plan, avoiding unnecessary surgical treatment, improving the quality of life of patients, reducing mortality. This project will further integrate the adrenal cortex and medulla hormone mass spectrometry detection and the molecular markers of adrenal tumors through phenotypic, functional imaging, and molecular pathological evaluations, and built a sensitive drug screening platform that integrates visual drug response and molecular characteristics, thereby achieving precise diagnosis and treatment of complicated adrenal tumors.
연구 개요
연구 유형
등록 (예상)
연락처 및 위치
연구 연락처
- 이름: Yiran Jiang, MD
- 전화번호: 8621-64370045
- 이메일: rainy0409@hotmail.com
연구 연락처 백업
- 이름: Luming Wu, PhD
- 전화번호: 8621-64370045
- 이메일: wulum@126.com
연구 장소
-
-
Shanghai
-
Shanghai, Shanghai, 중국, 200025
- 모병
- Ruijin Hospital
-
연락하다:
- Yiran Jiang
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Inclusion Criteria:
- Age ≥ 18 years old and ≤ 75 years
- Diagnosis of Patients with primary aldosteronism, pheochromocytoma, and cortical cancer
- Gender: males and females
- Provide written informed consent
- Satisfactory compliance
Exclusion Criteria:
- Patients with renal insufficiency (Cr>2 times the upper limit of normal).
- Patients with a history of liver cirrhosis.
- Patients who are currently using corticosteroids.
- Patients with cardiac insufficiency (NYHA cardiac function classification grade 3 and above or EF<50%).
- Patients with stroke and acute myocardial infarction in the past 6 months.
- Patients during pregnancy and lactation
설명
Inclusion Criteria:
- Age ≥ 18 years old and ≤ 75 years
- Diagnosis of Patients with primary aldosteronism, pheochromocytoma, and cortical cancer
- Gender: males and females
- Provide written informed consent
- Satisfactory compliance
Exclusion Criteria:
- Patients with renal insufficiency (Cr>2 times the upper limit of normal).
- Patients with a history of liver cirrhosis.
- Patients who are currently using corticosteroids.
- Patients with cardiac insufficiency (NYHA cardiac function classification grade 3 and above or EF<50%).
- Patients with stroke and acute myocardial infarction in the past 6 months.
- Patients during pregnancy and lactation
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
1 차 알도스테론주의
|
pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results
|
|
pheochromocytoma
|
pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results
|
|
adrenocortical carcinoma
|
pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
tumor biochemical marker treatment response
기간: 20 years
|
|
20 years
|
|
Tumor volume assessment: According to RECIST (version 1.1).
기간: 20 years
|
|
20 years
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
surgery or drug에 대한 임상 시험
-
Stryker Craniomaxillofacial모집하지 않고 적극적으로하악 골절 | 안면 골절 | 상악 골절 | 악교정 수술 절차미국
-
Devintec SaglMeditrial SrL모병
-
Anne Louise Tølbøll Sørensen아직 모집하지 않음
-
Sinotau Pharmaceutical Group모병